关注并星标CPHI制药在线在6月11日这一天,"GLP-1(胰高血糖素样肽1)双雄"诺和诺德、礼来分别官宣新BD。诺和诺德与生物技术公司Deep Apple Therapeutics达成合作协议,旨在开发针对非肠促胰岛素G蛋白偶联受体(GPCR)靶点的小分子药物,交易总金额约8.12亿美元。礼来则与Juvena Therapeutics达成了一项超6.5亿美元的合作协议,携手开发增肌药物。两家公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.